Promising Results: SOL-257 Gene Therapy Benefits ALS Mouse Models

SOL-257, an experimental gene therapy developed by Sola Biosciences, has shown promising results in two mouse models of amyotrophic lateral sclerosis (ALS). The therapy targets the toxic TDP-43 protein that accumulates in ALS nerve cells and significantly improved disease outcomes, including extended survival, improved muscle strength, and motor function. SOL-257 works by promoting proper folding or degradation of misfolded TDP-43 proteins. The therapy utilizes Sola's JUMP70 technology platform and a harmless adeno-associated virus to deliver the gene therapy. These preclinical findings support the potential of SOL-257 as a translational therapy for ALS patients.